Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.

Date Founded



34 Crosby Drive,Suite 105,Bedford, MA 01730

Type of Company


Employees (Worldwide)



Hospitals & Patient Services
Medical Products & Equipment

Company Description

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Contact Data
Trying to get in touch with decision makers at Ocular Therapeutix, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer & Director

Chief Financial Officer & Principal Accounting Officer

Chief Operating Officer

General Counsel

Chief Technology Officer

Chief Medical Officer

Senior Vice President, Head-Business & Corporate Development

Head of Business & Corporate Development

Senior Vice President-Commercial

Senior Vice President, Clinical Development

Board of Directors

Managing Director at Versant Venture Management LLC

Medical Director at Midwest Surgical Services, Inc.

Director & Secretary at The Retina Society

Venture Partner at SV Health Investors LLP

Founder at ImmusanT, Inc.

President, Chief Executive Officer & Director at Ocular Therapeutix, Inc.

Former Senior Vice President, Head-Research & Development at Celltrion, Inc.

Paths to Ocular Therapeutix, Inc.
Potential Connections via
Relationship Science
Ocular Therapeutix, Inc.
Owners & Shareholders
Details Hidden

Opaleye Management's strategy for managing their fund is to actively invest, both long and short, in equity securities of US and foreign small and mid-cap biotechnology and specialty pharmaceutical and device companies, which may include private companies. Typically, these are companies that are developing therapies and treatments intended for humans. The fund focuses its long investments in equity securities of companies that may not be profitable yet but whose share price may grow significantly in the near term or over a 1-2 year or longer period based on their therapeutic development and financial objectives. The fund also aims to actively invest in stock and derivative transactions to profit from binary events, such as clinical data milestones or a US Food and Drug Administration (FDA) regulatory decision. Conversely, the fund seeks opportunities to short securities that have extended valuations relative to the marketplace. Opaleye Management employs a research process that involves analyzing company fundamentals, such as asset valuations, quality of management, likely catalysis and/ or innovative products and the competition.

Details Hidden

Summer Road specializes in global arbitrage investment strategies.

Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Recent Transactions
Details Hidden

Ocular Therapeutix, Inc. issued USD Common Stock

Details Hidden

Ocular Therapeutix, Inc. issued USD Common Stock

Details Hidden

Ocular Therapeutix, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Transaction Advisors

Advised onOcular Therapeutix, Inc. issued USD Common Stock

Escrow Agent

Advised onOcular Therapeutix, Inc. issued USD Common Stock

Legal Advisor

Advised onOcular Therapeutix, Inc. issued USD Common Stock

Co-Chair, Capital Markets Group

Advised onOcular Therapeutix, Inc. issued USD Common Stock


Advised onOcular Therapeutix, Inc. issued USD Common Stock

Managing Director

Advised onOcular Therapeutix, Inc. issued USD Common Stock

Advisors & Consultants

Chairman of the Board, Chief Executive Officer, Founder at Instylla, Inc.

Senior Advisor

Founder at Anchor Biotech Consulting


Managing Director at Westwicke Partners LLC

Key Stats and Financials As of 2019
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Debt
Total Equity
Enterprise Value / Sales
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Non-Profit Donations & Grants
$5,000 - $10K
$5,000 - $10K
$5,000 - $10K
Details Hidden

SV Health Investors invests in companies located in North America and Europe. The firm targets companies operating in the fields of biotechnology, pharmaceuticals, medical devices & instruments, healthcare services. It provides financing for seed, early, later stage and buyout capital requirements.

Details Hidden

Founded in 1993, SV Health Investors LLC is a venture capital firm headquartered in Boston. The firm is a subsidiary of SV Life Sciences Advisers LLP, a venture capital investment firm based in London. SV Health Investors was formerly known as Schroder Ventures Life Sciences. They advise and manage several venture capital funds for corporate clients and private individuals.

Details Hidden

Chairman & Chief Executive Officer at Imperative Care, Inc.

Incept LLC Other Business & Consulting Services | San Mateo, CA

Incept LLC operates as a biotechnical research company. It focuses in the life-sciences space, and occasional involvement in select information technology opportunities. The company was founded in 1998 by Farhad Khosravi and Amarpreet S. Sawhney and is headquartered in San Mateo, CA.

Becton, Dickinson & Co. Medical Products & Equipment - Franklin Lakes, New Jersey

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. BD is headquartered in the United States and has offices in more than 50 countries worldwide.

EyePoint Pharmaceuticals, Inc. Pharmaceuticals - Watertown, MA

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ocular Therapeutix, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ocular Therapeutix, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Ocular Therapeutix, Inc..